[go: up one dir, main page]

WO2002002122A1 - Gouttes ophtalmologiques ayant un effet anti-inflammatoire fabriquees a partir d'un antibiotique a large spectre et d'un glucocorticoide local - Google Patents

Gouttes ophtalmologiques ayant un effet anti-inflammatoire fabriquees a partir d'un antibiotique a large spectre et d'un glucocorticoide local Download PDF

Info

Publication number
WO2002002122A1
WO2002002122A1 PCT/SK2001/000018 SK0100018W WO0202122A1 WO 2002002122 A1 WO2002002122 A1 WO 2002002122A1 SK 0100018 W SK0100018 W SK 0100018W WO 0202122 A1 WO0202122 A1 WO 0202122A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
distilled water
azidamphenicol
sodium
dexamethasone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SK2001/000018
Other languages
English (en)
Inventor
Vladimir Jancus
Jozef Ambro
Elena SLUCIAKOVÁ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unimed Pharma sro
Original Assignee
Unimed Pharma sro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unimed Pharma sro filed Critical Unimed Pharma sro
Priority to PL01354056A priority Critical patent/PL354056A1/xx
Priority to UA2002031750A priority patent/UA53917A/uk
Priority to AU2001266548A priority patent/AU2001266548A1/en
Priority to ROA200200235A priority patent/RO121087B1/ro
Publication of WO2002002122A1 publication Critical patent/WO2002002122A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Definitions

  • Present technical solution relates to ophthalmological drops with anti- inflammatory effect based on a wide-spectrum antibiotic and a local glucocorticoid.
  • a number of ophthalmological preparations, known so far, based on a wide- spectrum antibiotic and a local glucocorticoid is now complemented with drops according to the present technical solution, the nature of which consists in that they contain from 0.1 to 2 % by weight of the wide-spectrum antibiotic azidamphenicol and from 0.01 to 1 % by weight of glucocorticoid dexamethasone or possibly its phosphate or acetate salt as the active substance, further from 0.0005 to 0.1 % by weight of a preserving additive, from 0.001 to 2 % by weight of substances which keep the pH value of the medium within a range from 4.5 to 7.5, from 0.01 to 5 % by weight of substances which ensure viscosity of the medium to be within a range of 5 to 25 mPa.s, and the rest to 100 % by weight consists of distilled water.
  • the substances which keep the pH value of the medium within a range from 4.5 to 7.5 include sodium acetate, sodium chloride, boric acid, borax, disodium edetate, sodium hydrogen phosphate or sodium dihydrogeri phosphate, alone or in a mixture.
  • the substances which ensure viscosity of the medium to be within a range of 5 to 25 mPa.s include hydroxypropylmethylcellulose, polyvinyl alcohol, polyoxyethylenesorbitan monooleate, alone or in a mixture.
  • the preserving additive is benzalkonium chloride, carbetopendecinium bromide, thimerosal, chlorohexidine or chlorobutanol.
  • azidamphenicol is a synthetic analogue of the wide- spectrum antibiotic chloramphenicol with identical antimicrobial spectrum. It is liposoluble, it diffuses through a bacterial membrane and it binds to ribosomes, it hinders bacterial proteosynthesis by inhibiting the peptide synthetase. At higher doses it acts bacteriostatically on a wide spectrum of microorganisms and even bactericidally on certain sensitive microorganisms. Probability of resistance is minimal. When applied topically to an eye it shows low toxicity and is well " tolerated by the eye tissue.
  • the second active substance is dexamethasone, a synthetic monofluorinated glucocorticoid without a mineralocorticoidal effect which is present in the form of a sodium salt.
  • Dexamethasone shows very strong and pronounced anti-inflammatory effect, combined with an antiallergic, analgesic and antiproliferative effect.
  • Indications for the combined preparation according to the present solution include inflammatory processes of the eye structures where anti-inflammatory effect is required together with simultaneous suppression of arising or of a risk of arising of secondary bacterial infection.
  • An advantage of the eye drops according to the present solution is a simultaneous good efficiency and stability at temperatures of up to 25 °C.
  • the amounts of components of a production batch are a linear function of the amounts per one package, i. e. 10 ml.
  • composition for one package azidamphenicol 0.01000 g dexamethasone sodium phosphate 0.00100 g sodium acetate 0.01000 g boric acid 0.01000 g borax - 0.00100 g disodium edetate 0.00010 g polysorbate 0.00100 g hydroxypropylmethylcellulose 0.00100 g thimerosal 0.00005 g
  • composition for one package azidamphenicol 0.01000 g dexamethasone sodium phosphate 0.00100 g sodium acetate 0.01000 g boric acid 0.01000 g polysorbate 0.00100 g disodium edetate 0.00010 g polyvinyl alcohol 0.00100 g benzalkonium chloride 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.01000 g dexamethasone sodium phosphate 0.00100 g sodium acetate 0.01000 g polysorbate 0.00100 g hydroxypropylmethylcellulose 0.00100 g chlorohexidine 0.00005 g sterilized distilled water ad 10 ml d) Composition for one package: azidamphenicol 0.01000 g dexamethasone sodium phosphate 0.00100 g boric acid 0.01000 g disodium edetate 0.00010 g hydroxypropylmethylcellulose 0.00100 g thimerosal 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.01000 g dexamethasone sodium phosphate 0.00100 g sodium hydrogen phosphate 0.01000 g sodium dihydrogen phosphate 0.01000 g disodium edetate 0.00010 g hydroxypropylmethylcellulose 0.00100 g chlorobutanol 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.01000 g dexamethasone sodium phosphate 0.00100 g sodium chloride 0.00100 g disodium edetate 0.00010 g hydroxypropylmethylcellulose 0.00100 g carbetopendecinium bromide 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.01000 g dexamethasone 0.00100 g sodium acetate 0.01000 g boric acid 0.01000 g borax 0.00100 g disodium edetate 0.00010 g polysorbate 0.00100 g hydroxypropylmethylcellulose 0.00100 g thimerosal 0.00005 g sterilized distilled water ad 10 ml h) Composition for one package: azidamphenicol 0.01000 g dexamethasone 0.00100 g sodium acetate 0.01000 g boric acid 0.01000 g polysorbate 0.00100 g disodium edetate 0.00010 g polyvinyl alcohol 0.00100 g benzalkonium chloride 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.01000 g dexamethasone 0.00100 g sodium acetate 0.01000 g polysorbate 0.00100 g hydroxypropylmethylcellulose 0.00100 g chlorohexidine 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.01000 g dexamethasone 0.00100 g boric acid 0.01000 g disodium edetate 0.00010 g hydroxypropylmethylcellulose 0.00100 g thimerosal 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.01000 g dexamethasone 0.00100 g sodium hydrogen phosphate 0.01000 g sodium dihydrogen phosphate 0.01000 g disodium edetate 0.00010 g hydroxypropylmethylcellulose 0.00100 g chlorobutanol 0.00005 g sterilized distilled water ad 10 ml 1)
  • Composition for one package azidamphenicol 0.01000 g dexamethasone 0.00100 g sodium chloride 0.00100 g disodium edetate 0.00010 g hydroxypropylmethylcellulose 0.00100 g carbetopendecinium bromide 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.01000 g dexamethasone acetate 0.00100 g sodium acetate 0.01000 g boric acid 0.01000 g borax 0.00100 g disodium edetate 0.00010 g polysorbate 0.00100 g hydroxypropylmethylcellulose 0.00100 g thimerosal 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package: azidamphenicol 0.01000 g dexamethasone acetate 0.00100 g sodium acetate 0.01000 g boric acid 0.01000 g polysorbate 0.00100 g disodium edetate 0.00010 g polyvinyl alcohol 0.00100 g benzalkonium chloride 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.01000 g dexamethasone acetate 0.00100 g sodium acetate 0.01000 g polysorbate 0.00100 g hydroxypropylmethylcellulose 0.00100 g chlorohexidine 0.00005 g sterilized distilled water ad 10 ml
  • Composition for one package azidamphenicol 0.01000 g dexamethasone acetate 0.00100 g boric acid 0.01000 g disodium edetate 0.00010 g hydroxypropylmethylcellulose 0.00100 g thimerosal 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.01000 g dexamethasone acetate 0.00100 g sodium hydrogen phosphate 0.01000 g sodium dihydrogen phosphate 0.01000 g disodium edetate 0.00010 g hydroxypropylmethylcellulose . 0.00100 g chlorobutanol 0.00005 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.01000 g dexamethasone acetate 0.00100 g sodium chloride 0.00100 g disodium edetate 0.00010 g hydroxypropylmethylcellulose 0.00100 g carbetopendecinium bromide 0.00005 g sterilized distilled water ad 10 ml
  • the amounts of components of a production batch are a linear function of the amounts per one package, i. e. 10 ml.
  • composition for one package azidamphenicol 0.20000 g dexamethasone sodium phosphate 0.20000 g sodium acetate 0.20000 g boric acid 0.20000 g polysorbate 0.50000 g disodium edetate 0.02000 g polyvinyl alcohol 0.50000 g benzalkonium chloride 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.20000 g dexamethasone sodium phosphate 0.20000 g sodium acetate 0.20000 g polysorbate 0.50000 g hydroxypropylmethylcellulose 0.20000 g chlorohexidine 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.20000 g dexamethasone sodium phosphate 0.20000 g boric acid 0.20000 g disodium edetate 0.02000 g hydroxypropylmethylcellulose 0.20000 g thimerosal 0.01000 g sterilized distilled water ad 10 ml e) Composition for one package: azidamphenicol 0.20000 g dexamethasone sodium phosphate 0.20000 g sodium hydrogen phosphate 0.20000 g sodium dihydrogen phosphate 0.20000 g disodium edetate 0.02000 g hydroxypropylmethylcellulose 0.20000 g chlorobutanol 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.20000 g dexamethasone sodium phosphate 0.20000 g sodium chloride 0.20000 g disodium edetate 0.02000 g hydroxypropylmethylcellulose 0.20000 g carbetopendecinium bromide 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.20000 g dexamethasone 0.20000 g sodium acetate 0.20000 g boric acid 0.20000 g borax 0.20000 g disodium edetate 0.02000 g polysorbate 0.50000 g hydroxypropylmethylcellulose 0.20000 g thimerosal 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.20000 g dexamethasone 0.20000 g sodium acetate 0.20000 g boric acid 0.20000 g polysorbate 0.50000 g sodium edetate 0.02000 g polyvinyl alcohol 0.50000 g benzalkonium chloride 0.01000 g sterilized distilled water ad 10 ml
  • Composition for one package azidamphenicol 0.20000 g dexamethasone 0.20000 g sodium acetate 0.20000 g polysorbate 0.20000 g hydroxypropylmethyl cellulose 0.20000 g chlorohexidine 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.20000 g dexamethasone 0.20000 g boric acid 0.20000 g disodium edetate 0.02000 g hydroxypropylmethylcellulose 0.20000 g thimerosal 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.20000 g dexamethasone 0.20000 g - sodium hydrogen phosphate 0.20000 g sodium dihydrogen phosphate 0.20000 g disodium edetate 0.02000 g hydroxypropylmethylcellulose 0.20000 g chlorobutanol 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.20000 g dexamethasone 0.20000 g sodium chloride 0.20000 g disodium edetate 0.02000 g hydroxypropylmethylcellulose 0.20000 g carbetopendecinium bromide 0.01000 g sterilized distilled water ad 10 ml m)
  • Composition for one package azidamphenicol 0.20000 g dexamethasone acetate 0.20000 g sodium acetate 0.20000 g boric acid 0.20000 g borax 0.20000 g disodium edetate 0.02000 g polysorbate 0.50000 g hydroxypropylmethylcellulose 0.20000 g thimerosal 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.20000 g dexamethasone acetate 0.20000 g sodium acetate 0.20000 g boric acid 0.20000 g polysorbate 0.50000 g disodium edetate 0.02000 g polyvinyl alcohol 0.20000 g benzalkonium chloride 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.20000 g dexamethasone acetate 0.20000 g sodium acetate 0.20000 g polysorbate 0.50000 g hydroxypropylmethylcellulose 0.20000 g chlorohexidine 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.20000 g dexamethasone acetate 0.20000 g boric acid 0.20000 g disodium edetate 0.02000 g hydroxypropylmethylcellulose 0.20000 g thimerosal 0.01000 g sterilized distilled water ad 10 ml q) Composition for one package: azidamphenicol 0.20000 g dexamethasone acetate 0.20000 g sodium hydrogen phosphate 0.20000 g sodium dihydrogen phosphate 0.20000 g disodium edetate 0.02000 g hydroxypiOpylmethylcellulose 0.20000 g chlorobutanol 0.01000 g sterilized distilled water ad 10 ml
  • composition for one package azidamphenicol 0.20000 g dexamethasone acetate 0.20000 g sodium chloride 0.20000 g disodium edetate 0.02000 g hydroxypropylmethylcellulose 0.20000 g carbetopendecinium bromide 0.01000 g sterilized distilled water ad 10 ml
  • the eye drops according to the present technical solution can be utilized in ophthalmology in the case of inflammatory processes of the eye structures, where combined anti-inflammatory and antibacterial treatment is useful, in particular eye inflammations which are sensitive to glucocorticoids and which are accompanied with bacterial infection or where a risk of bacterial infection of the eye exists.
  • eye inflammations which are sensitive to glucocorticoids and which are accompanied with bacterial infection or where a risk of bacterial infection of the eye exists.
  • eye inflammations which are sensitive to glucocorticoids and which are accompanied with bacterial infection or where a risk of bacterial infection of the eye exists.
  • These are, for example, blepharoco ⁇ junctivitis, superficial keratitis (nonpurulent, nonviral), inflammatory processes of sclera, chronical and acute allergic conjunctivitis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des gouttes ophtalmologiques ayant un effet anti-inflammatoire fabriquées à partir d'un antibiotique à large spectre et d'un glucocorticoïde local contenant de 0,1 à 2 % en poids d'azidamphenicol; de 0,01 à 1 % en poids de dexaméthasone ou des sels phosphates ou acétates de celle-ci comme principe actif; de 0,0005 à 0,1 % en poids d'un additif de conservation; de 0,001 à 2 % en poids de substances maintenant la valeur de pH du milieu dans une gamme comprise entre 4,5 et 7,5; de 0,01 à 5 % en poids de substances garantissant la viscosité du milieu dans une gamme comprise entre 5 et 25 mPas.s; le reste des 100 % en poids consistant en de l'eau distillée.
PCT/SK2001/000018 2000-07-03 2001-06-25 Gouttes ophtalmologiques ayant un effet anti-inflammatoire fabriquees a partir d'un antibiotique a large spectre et d'un glucocorticoide local Ceased WO2002002122A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL01354056A PL354056A1 (pl) 2000-07-03 2001-06-25 Krople okulistyczne wykazujące działanie przeciwzaKrople okulistyczne wykazujące działanie przeciwzapalne oparte na antybiotyku o szerokim działaniu ipalne oparte na antybiotyku o szerokim działaniu i miejscowym glukokortykoidzie miejscowym glukokortykoidzie
UA2002031750A UA53917A (uk) 2000-07-03 2001-06-25 Офтальмологічні краплі з протизапальною дією на основі антибіотика широкого спектра дії і локального глюкокортикоїду
AU2001266548A AU2001266548A1 (en) 2000-07-03 2001-06-25 Ophthalmological drops with anti-imflammatory effect based on a wide-spectrum antibiotic and a local glucocorticoid
ROA200200235A RO121087B1 (ro) 2000-07-03 2001-06-25 Picături oftalmice cu efect antiinflamator

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SKPUV0223-2000 2000-07-03
SK223-2000U SK2845U (sk) 2000-07-03 2000-07-03 Oftalmologické kvapky s protizápalovým účinkom na báze širokospektrálneho antibiotika a lokálneho glukokortikoidu

Publications (1)

Publication Number Publication Date
WO2002002122A1 true WO2002002122A1 (fr) 2002-01-10

Family

ID=20435772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SK2001/000018 Ceased WO2002002122A1 (fr) 2000-07-03 2001-06-25 Gouttes ophtalmologiques ayant un effet anti-inflammatoire fabriquees a partir d'un antibiotique a large spectre et d'un glucocorticoide local

Country Status (9)

Country Link
AU (1) AU2001266548A1 (fr)
CZ (1) CZ12190U1 (fr)
FR (1) FR2812196B3 (fr)
PL (1) PL354056A1 (fr)
RO (1) RO121087B1 (fr)
RU (1) RU2002107305A (fr)
SK (1) SK2845U (fr)
UA (1) UA53917A (fr)
WO (1) WO2002002122A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008099210A2 (fr) 2007-02-12 2008-08-21 Merck & Co., Inc. Dérivés de pipérazine pour le traitement de la maladie d'alzheimer et des conditions apparentées
WO2009128057A2 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
RU2504372C1 (ru) * 2012-09-07 2014-01-20 Илья Александрович Марков Глазные капли

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2506086C1 (ru) * 2012-09-07 2014-02-10 Илья Александрович Марков Глазные капли, обладающие противовоспалительным и антибактериальным действием

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56104814A (en) * 1980-01-25 1981-08-20 Kunihiro Okanoe Preparation of eye drop

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56104814A (en) * 1980-01-25 1981-08-20 Kunihiro Okanoe Preparation of eye drop

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BEDAIR MM; KORANY MA; ELSAYED MA; FAHMY OT: "Derivative spectrophometric determination of clotrimazole in single formulations and in combination with other drugs", JOURNAL OF THE ASSOCIATION OF OFFICIAL ANALYTICAL CHEMISTS, vol. 72, no. 3, 1989, pages 432 - 435, XP001024435 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; OKANOUE, JOTSUNE, JAPAN: "Eye lotions containing olive oil", XP002180608, retrieved from STN Database accession no. 95:192402 CA *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; STUCHLIK, M. ET AL: "Ophthalmic drugs - some aspects of industrial manufacture", XP002180609, retrieved from STN Database accession no. 93:120358 CA *
GRINBLAT M: "CLINICAL EVALUATION OF THE TOPICAL ASSOCIATION OF DEXAMETHASONE CLOTRIMAZOLE AND AZIDOAMPHENICOL", FOLHA MEDICA, vol. 82, no. 1, 1981, pages 71 - 72, XP001024434, ISSN: 0015-5454 *
ROZVOJ FARM. RAMCI VED.-TECH. REVOLUCE, SB. PREDNASEK SJEZDU CESK. FARM. SPOL., 7TH (1979), MEETING DATE 1977, 253-6 PUBLISHER: UNIV. KARLOVA, PRAGUE, CZECH. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008099210A2 (fr) 2007-02-12 2008-08-21 Merck & Co., Inc. Dérivés de pipérazine pour le traitement de la maladie d'alzheimer et des conditions apparentées
WO2009128057A2 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
RU2504372C1 (ru) * 2012-09-07 2014-01-20 Илья Александрович Марков Глазные капли

Also Published As

Publication number Publication date
FR2812196A3 (fr) 2002-02-01
SK2845U (sk) 2001-05-10
RU2002107305A (ru) 2004-01-27
CZ12190U1 (cs) 2002-04-15
FR2812196B3 (fr) 2002-06-28
UA53917A (uk) 2003-02-17
PL354056A1 (pl) 2003-12-15
RO121087B1 (ro) 2006-12-29
AU2001266548A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
EP0139535B1 (fr) Compositions pour combattre la toxaemie
US4829083A (en) Stabilization of mercury-containing preservatives in ophthalmic medicaments
US6599944B1 (en) Ophtalmic compound with extended dwell time on the eye
EP1073467B1 (fr) Formulations de co-solvants contenant de vitamin d
US3070499A (en) Parenteral aqueous solutions of fat soluble vitamins
ZA200206688B (en) Esmolol formulation.
WO2013112762A1 (fr) Compositions de bendamustine et procédés associés
CN112868662A (zh) 一种低温高效复方消毒剂及其制备方法
WO2002002122A1 (fr) Gouttes ophtalmologiques ayant un effet anti-inflammatoire fabriquees a partir d'un antibiotique a large spectre et d'un glucocorticoide local
FI75991B (fi) Foerfarande foer framstaellning av stabil isotonisk vaetskekomposition, vilken kan anvaendas som oegonmedicinpreparat.
JPH10203960A (ja) 点眼液組成物
US3944668A (en) Antimicrobial compositions
EP1905453B1 (fr) Composition conservatrice à usage ophtalmique
WO2003068247A1 (fr) Instillation oculaire a base d'anions d'iode
US3639623A (en) Topical pharmaceutical composition comprising certain quaternary ammonium compounds
US3322627A (en) Method of treating herpes simplex infections with 5-methylamino-2'-deoxyuridine, and compositions therefor
JP2004123634A (ja) 眼科用組成物
EP0076430B1 (fr) Composition à activité microbicide
IE902790A1 (en) Formulations of phenytoin sodium for intravenous¹administration
JP4683835B2 (ja) 防腐剤及びこれを含有する水性組成物
HK63991A (en) Stable injectable pharmaceutical formulation for 1,4-dihydroxy-5,8-bis((2-(hydroxyethylamino)-ethyl)amino)anthraquinone, dihydrochloride
KR20120046026A (ko) 소프트 콘택트 렌즈용 안과 조성물
GB1562902A (en) Pharmaceutical compositions containing clavulanic acid
US20080287543A1 (en) Pharmaceutical composition comprising 5-methyl-2 (2'-chloro-6'-fluoroanillino) phen ylacetic acid
EP1663147A1 (fr) Formulations de derives d'anthraquinone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PUV2002-12867

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2002 200200235

Country of ref document: RO

Kind code of ref document: A

ENP Entry into the national phase

Ref country code: RU

Ref document number: 2002 2002107305

Kind code of ref document: A

Format of ref document f/p: F

WWG Wipo information: grant in national office

Ref document number: PUV2002-12867

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP